Frederic Hollande

BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006.

BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006.

BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006.

BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006.

BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006.